Literature DB >> 2438035

Immunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal, and neuroendocrine antigens.

J L Broers, M K Rot, T Oostendorp, A Huysmans, S S Wagenaar, A J Wiersma-van Tilburg, G P Vooijs, F C Ramaekers.   

Abstract

Lung cancers were investigated for their heterogeneity as expressed by their immunoreactivity for cytokeratins and neurofilament proteins, as well as for the neuroendocrine differentiation antigen MOC-1. Using broadly cross-reacting antibodies, cytokeratins were detected in nearly all cases of lung carcinomas. Keratinization could be detected only in cases of moderately to well-differentiated squamous cell carcinoma (SQC) using a monoclonal antibody to cytokeratin 10, while a monoclonal antibody reactive with cytokeratin 18, and specific for glandular epithelia, reacted with adenocarcinomas, small cell lung carcinomas (SCLC), and lung carcinoids. In SQC this antibody could detect non-squamous cell differentiation, showing increasing numbers of positive cells with decrease of histologically detectable SQC differentiation. Cells positive for neurofilaments were demonstrated in some of the poorly differentiated SQCs and in some of the cases of SCLC, possibly representing the variant type of SCLC. Also in some of the lung carcinoids neurofilament proteins were present, colocalizing with cytokeratins. MOC-1 was present in all SCLC and lung carcinoids. This antibody could also detect neuroendocrine differentiation in all combined small cell carcinomas, in one poorly differentiated adenocarcinoma, and in about 30% of the poorly differentiated SQCs. Therefore, lung cancer heterogeneity can be detected using a panel of well-defined antibodies to intermediate filaments in combination with the MOC-1 antibody. The use of these antibodies in diagnosis can have prognostic significance and can lead to a more selective therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438035

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Expression of 'small cell carcinoma antigens' in primary small cell lung cancer and metastases: an immunohistochemical study.

Authors:  B G Skov; F R Hirsch; F G Hay; J E Olsen; L G Bobrow
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis.

Authors:  A T Myklebust; K Beiske; A Pharo; C D Davies; S Aamdal; O Fodstad
Journal:  Br J Cancer Suppl       Date:  1991-06

3.  Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib.

Authors:  Minehiko Inomata; Ryuji Hayashi; Azusa Yamamoto; Kotaro Tokui; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Kensuke Suzuki; Tomomi Ichikawa; Toru Yamada; Toshiro Miwa; Tatsuhiko Kashii; Shoko Matsui; Kazuyuki Tobe; Johji Imura
Journal:  Mol Clin Oncol       Date:  2015-05-14

Review 4.  Intermediate filaments in the nervous system: implications in cancer.

Authors:  C L Ho; R K Liem
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

5.  The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells.

Authors:  E B van Dorst; G N van Muijen; S V Litvinov; G J Fleuren
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

6.  Importance of sampling method in DNA analysis of lung cancer.

Authors:  F A Carey; D Lamb; C C Bird
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

7.  Nuclear A-type lamins are differentially expressed in human lung cancer subtypes.

Authors:  J L Broers; Y Raymond; M K Rot; H Kuijpers; S S Wagenaar; F C Ramaekers
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

8.  Distribution patterns of type VII collagen in normal and malignant human tissues.

Authors:  R H Wetzels; H C Robben; I M Leigh; H E Schaafsma; G P Vooijs; F C Ramaekers
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

9.  The relevance of flow-cytometric DNA content in the evaluation of lung cancer.

Authors:  F Salvati; L Teodori; M L Trinca; R Pasquali-Lasagni; W Göhde
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Authors:  Kathleen R Whiteman; Holly A Johnson; Michele F Mayo; Charlene A Audette; Christina N Carrigan; Alyssa LaBelle; Lawrence Zukerberg; John M Lambert; Robert J Lutz
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.